A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies
Not Applicable
Active, not recruiting
- Conditions
- Gastric (Stomach) CancerEsophageal Cancer
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Target Recruit Count
- 150
- Registration Number
- NCT06997302
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Multicenter Randomized Controlled Clinical Trial of the Impact of Minimally Invasive Abdominal Surgery Esophageal Pressure Monitoring Guided Individualized PEEP on Postoperative Pulmonary Complications in Obese Patients
Not Applicable
Not yet recruiting
- Conditions
- PostoperativePulmonaryComplications
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Target Recruit Count
- 180
- Registration Number
- NCT06996288
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Phase 2
Not yet recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: Ivonescimab+chemotherapy
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 30
- Registration Number
- NCT06993025
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor, Malignant Ascites
- Interventions
- Drug: SK-NK injection
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 10
- Registration Number
- NCT06991478
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: GK01 Injection
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 15
- Registration Number
- NCT06954558
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 33
- Registration Number
- NCT06951997
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-31
- Target Recruit Count
- 30
- Registration Number
- NCT06944106
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Phase 2
Recruiting
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Interventions
- Drug: Neoadjuvant Cryoablation Combined with Tislelizumab and ChemotherapyProcedure: Surgery
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 38
- Registration Number
- NCT06939127
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 48
- Registration Number
- NCT06938503
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Phase 2
Recruiting
- Conditions
- Endometrial AdenocarcinomaEndometrial Cancer
- Interventions
- Drug: QL1706 combined with chemotherapy ± Bevacizumab
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 30
- Registration Number
- NCT06917092
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China